




PHARMACEUTICAL 2020

Strongbridge Biopharma plc
Rank 170 of 358





PHARMACEUTICAL 2020

Strongbridge Biopharma plc
Rank 170 of 358

The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Strongbridge Biopharma plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 55% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	83,543
Cost of Goods Sold	0
Intangible Assets	32,366
Liabilities, Current	24,293
Liabilities, Non-Current	1,080
Other Assets	1,438
Other Compr. Net Income	3.0
Other Expenses	10,612
Other Liabilities	20,074
Other Net Income	19,410
Other Revenues	21,712
Property and Equipment	291
Research and Development	30,903
Selling, General and Administrative Expense	49,058

Output Variable	Value in 1000 USD
Assets	117,638
Liabilities	45,447
Expenses	90,573
Revenues	21,712
Stockholders Equity	72,191
Net Income	-49,451
Comprehensive Net Income	-49,450
Economic Capital Ratio	92%